Human Heredity and Health in Africa Consortium Biorepository

项目摘要 非洲人类遗传与健康（H3 Africa）是在国家卫生和公共卫生部的资助下成立的。 卫生研究所共同基金和惠康信托基金，目的是扩大基因组 非洲大陆的研究能力。资助项目的一个关键组成部分 在H3非洲下，数据和生物标本共享，并确保收集生物标本， 为了进一步研究，建立了生物储存库。H3Africa Biorepository 临床实验室服务（CLS）是第一个扩大规模以满足H3 Africa需求的设施 项目它利用了CLS现有的生物储存库基础设施， 符合GCLP的临床病理学服务和临床试验部门。CLS是一个部门， 威特沃特斯兰德大学的研究部门，智慧健康联盟（WHC），提供 为CLS的所有项目提供行政和法律的协助。从2014年起的资助期内- 2019年，CLS生物储存库的基础设施得到了大幅扩展， 开发了所有来自NIH资助项目第一阶段的样本都是在 并根据最佳实践以及以下方面的道德、法律的和社会考虑进行存储： 存储在非洲。 CLS的H3 Africa生物储存库第二阶段资金的目标是继续 为来自H3 Africa的基因组DNA和其他样本类型提供高质量的存储设施 项目，同时继续存储用于临床试验，制药行业和其他研究 与合作伙伴保持一致，以符合其业务模式和具有竞争力的按服务收费定价结构。的 biorepository扩大了其增值样品处理设施，包括Next- 测序能力、自动化核酸提取和稀有细胞群分选 旨在为研究人员提供这些服务，同时建设能力和技术能力。 它还在编写针对非洲的生物储藏科学培训材料。CLS生物储存库 积极与各机构（包括威特沃特斯兰德大学和比勒陀利亚大学）合作， 国家政府（包括卫生部和科技部）， 包括非洲联盟在内的区域结构，以确保生物储存库基础设施 作为区域资源，并将继续倡导非洲生物储存库， 国际和区域论坛，包括国际生物学会， 环境知识库。

Project Summary Human Heredity and Health in Africa (H3Africa) was established with funding from both the National Institutes of Health Common Fund and the Wellcome Trust with the aim of expanding genomic research and research capacity on the Africa continent. A key component of the projects funded under H3Africa is data and biospecimen sharing and to ensure that biospecimens were collected and stored for additional research, biorepositories were established. The H3Africa Biorepository at Clinical Laboratory Services (CLS) was the first facility to be scaled-up to meet the needs of H3Africa projects. It leveraged on an existing biorepository infrastructure which was supported at CLS by a GCLP-compliant clinical pathology service and clinical trials division. CLS is a division of the University of Witwatersrand’s research division, the Wits Health Consortium (WHC) which provides administrative and legal assistance to all of CLS’s projects. During the funding period from 2014- 2019, the infrastructure at the CLS biorepository was expanded considerably and technical expertise was developed. All samples from NIH-funded projects in the first phase were collected, transported and stored in alignment with best practice and with the ethical, legal and societal considerations of storage in Africa. The goal of the H3Africa biorepository at CLS for the second phase of funding is to continue to provide a high-quality storage facility for genomic DNA and other sample types from the H3Africa projects while continuing to store for clinical trials, pharmaceutical industry and other research partners in alignment with its business model and competitive fee-for-service pricing structure. The biorepository has expanded its value-added sample processing facilities by including Next- Generation Sequencing capacity, automated nucleic acid extraction and rare cell population sorting and aims to provide these services to researchers while building capacity and technical competence. It is also developing Africa-specific training material for biorepository science. The CLS biorepository is actively partnering with institutions (including the Universities of Witwatersrand and Pretoria), national government (including the Departments of Health and Science and Technology) and regional structures including the African Union to ensure that the biorepository infrastructure is maintained as a regional resource and will continue to advocate for African biorepositories in international and regional forums including the International Society of Biological and Environmental Repositories.